Clinical Trial Update: A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo [Phase 3]

View source ↗

Summary

Phase 3 study comparing SCENESSE (afamelanotide) plus NB-UVB versus NB-UVB alone in vitiligo; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• SCENESSE (afamelanotide)

Snippet

Sponsor: Clinuvel, Inc. | Conditions: Vitiligo | Phase 3 | Status: ACTIVE_NOT_RECRUITING